DAY ONE BIOPHARMACEUTICALS, INC.
DAWNUnited States
20 filed reports · 305 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
| Figure | Latest fiscal year | Latest quarter |
|---|---|---|
| Revenue | $158MFY2025 · to Dec 31, 2025+20.6% from $131M10-K | $39.8MQ3 FY2025 · to Sep 30, 2025−57.6% from $93.8M10-Q |
| Net income | -$107BFY2025 · to Dec 31, 2025a year earlier: -$95.5B10-K/A | -$19.7MQ3 FY2025 · to Sep 30, 2025a year earlier: $37M10-Q |
| Operating income | -$128MFY2025 · to Dec 31, 2025a year earlier: -$217M10-K | -$24.3MQ3 FY2025 · to Sep 30, 2025a year earlier: $29.6M10-Q |
Filed reports
20 reports · Jun 2021 to Dec 2025Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 14 | 1,645 | Jun 2021 to Sep 2025 |
| Annual · 10-KSEC EDGAR | 4 | 1,455 | Dec 2021 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 2 | 320 | Dec 2024 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2025 | 10-K/A | Dec 31, 2025 | Apr 17, 2026 | 38 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 766 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 219 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 179 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 6, 2025 | 169 | Open |
| FY2024 | 10-K/A | Dec 31, 2024 | Mar 6, 2025 | 282 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Oct 30, 2024 | 124 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 2, 2024 | 89 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 6, 2024 | 81 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 26, 2024 | 250 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 6, 2023 | 123 | Open |
| FY2023 Q2 | 10-Q | Jun 30, 2023 | Aug 7, 2023 | 87 | Open |
Financial data
305 concepts · 3,420 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial304 concepts · 3,390 facts · Dec 2019 to Dec 2025
- Stockholders equity (US GAAP)32 · Dec 2019 to Dec 2025
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value31 · Dec 2019 to Dec 2025
- Allocated share based compensation expense31 · Dec 2019 to Dec 2025
- Cash and cash equivalents at carrying value31 · Dec 2019 to Dec 2025
- General and administrative expense (US GAAP)31 · Dec 2019 to Dec 2025
- Operating expenses (US GAAP)31 · Dec 2019 to Dec 2025
- Operating income loss31 · Dec 2019 to Dec 2025
- Research and development expense31 · Dec 2019 to Dec 2025
- Depreciation depletion and amortization29 · Dec 2019 to Dec 2025
- Increase decrease in accounts payable29 · Dec 2019 to Dec 2025
- Increase decrease in deposit other assets29 · Dec 2019 to Dec 2025
- Net cash provided by used in investing activities29 · Dec 2019 to Dec 2025
- Net cash provided by used in operating activities29 · Dec 2019 to Dec 2025
- Other nonoperating income expense29 · Dec 2019 to Dec 2025
- Antidilutive securities excluded from computation of earnings per share amount28 · Sep 2020 to Dec 2025
- Cash cash equivalents restricted cash and restricted cash equivalents28 · Dec 2019 to Dec 2025
- Increase decrease in prepaid deferred expense and other assets28 · Sep 2020 to Dec 2025
- Operating lease right of use asset amortization expense28 · Sep 2020 to Dec 2025
- Net cash provided by used in financing activities27 · Dec 2019 to Dec 2025
- Payments to acquire property plant and equipment27 · Dec 2019 to Dec 2025
- Accounts payable and accrued liabilities current26 · Dec 2020 to Dec 2025
- Accounts payable current26 · Dec 2020 to Dec 2025
- Accrued liabilities and other liabilities26 · Dec 2020 to Dec 2025
- Accrued professional fees current26 · Dec 2020 to Dec 2025
Product1 concept · 30 facts · Dec 2022 to Dec 2025
- Revenue30 · Dec 2022 to Dec 2025
Segments
30 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service2 members · 30 facts
- Product revenue, net [Member]16 · Dec 2022 to Dec 2025
- License revenue [Member]14 · Dec 2022 to Dec 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of DAY ONE BIOPHARMACEUTICALS, INC. (DAWN) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.